Skip to main content

Table 4 Seroconversion rates and geometric mean titers after vaccination compared to before vaccination (per-protocol population, homologous response)

From: Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial

  Time point Value KD-287 (n = 93) JEV-GCC (n = 95) *Difference/Ratio
SCR Seropositive at baseline n (%) 0 (0.0) 1 (1.0)  
95% CI    
After 2nd dose n (%) 93 (100.0) 93 (97.9) 2.1
95% CI    (−0.78, 4.99)
Before 3rd dose n (%) 93 (100.0) 90 (94.7) 5.3
95% CI    (0.77, 9.75)
After 3rd dose n (%) 93 (100.0) 94 (98.9) 1.1
95% CI (100.0, 100.0) (96.9, 100.0) (−1.00, 3.10)
GMT Before Vaccination log10n 5 5 1.0
95% CI (5, 6)   (1.0, 1.1)
After 2nd dose log10n 601 107 5.6
95% CI (509, 709) (84, 137) (4.2, 7.5)
Before 3rd dose log10n 917 45 20.1
95% CI (757, 1110) (36, 56) (15.2, 26.7)
After 3rd dose log10n 13347 967 13.8
95% CI (11455, 15551) (798, 1172) (10.8, 17.6)
  1. SCR, seroconversion rate; GMT, geometric mean titer; CI, confidence interval.
  2. *Difference is KD-287 minus JEV-GCC for SCR and ratio is KD-287 divided by JEV-GCC for GMT.
  3. The p-value was calculated using the t-test for GMT; p < 0.001 in all.